Sussman Gordon, Hébert Jacques, Gulliver Wayne, Lynde Charles, Waserman Susan, Kanani Amin, Ben-Shoshan Moshe, Horemans Spencer, Barron Carly, Betschel Stephen, Yang William H, Dutz Jan, Shear Neil, Lacuesta Gina, Vadas Peter, Kobayashi Kenneth, Lima Hermenio, Simons F Estelle R
University of Toronto, Medicine, Toronto, ON Canada.
Université Laval, Medicine, Quebec, QC Canada.
Allergy Asthma Clin Immunol. 2015 Feb 11;11(1):7. doi: 10.1186/s13223-015-0072-2. eCollection 2015.
In the past few years there have been significant advances which have changed the face of chronic urticaria. In this review, we aim to update physicians about clinically relevant advances in the classification, diagnosis and management of chronic urticaria that have occurred in recent years. These include clarification of the terminology used to describe and classify urticaria. We also detail the development and validation of instruments to assess urticaria and understand the impairment on quality-of-life and the morbidity caused by this disease. Additionally, the approach to management of chronic urticaria now focuses on evidence-based use of non-impairing, non-sedating H1-antihistamines given initially in standard doses and if this is not effective, in up to 4-fold doses. For urticaria refractory to H1-antihistamines, omalizumab treatment has emerged as an effective, safe option.
在过去几年里，取得了重大进展，改变了慢性荨麻疹的面貌。在本综述中，我们旨在向医生介绍近年来慢性荨麻疹在分类、诊断和管理方面的临床相关进展。这些进展包括对用于描述和分类荨麻疹的术语的澄清。我们还详细介绍了评估荨麻疹的工具的开发和验证，以及了解该疾病对生活质量的损害和发病率。此外，慢性荨麻疹的管理方法现在侧重于循证使用非镇静、非嗜睡的H1抗组胺药，最初给予标准剂量，如果无效，则给予高达4倍的剂量。对于对H1抗组胺药难治的荨麻疹，奥马珠单抗治疗已成为一种有效、安全的选择。
